Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17838322 | 0.87 | LPL (0.33) | — | |
| SCHEMBL22654957 | 0.84 | TSHR (0.41) | ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL29508529 | 0.84 | TSHR (0.41) | ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL30412775 | 0.82 | SELL (0.37) | HIF1AALDH1A1 | |
| SCHEMBL12845193 | 0.82 | RAPGEF4 (0.34) | ALDH1A1 | |
| SCHEMBL22655171 | 0.82 | SELL (0.37) | HIF1AALDH1A1 | |
| SCHEMBL30526615 | 0.82 | RAPGEF4 (0.34) | ALDH1A1 | |
| SCHEMBL22655066 | 0.81 | LPL (0.34) | ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL29508571 | 0.81 | LPL (0.34) | ALDH1A1HPGDTSHRHSD17B10 | |
| SCHEMBL31088896 | 0.79 | LPL (0.39) | HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-06-26 | — | — | US | disclosed |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | NODTHERA LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | HIF1A 3960/4885ALDH1A1 3601/4885HPGD 1295/4885 |
| US-20250115558-A1 | PYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NOD1 | HIF1A 1730/4885ALDH1A1 476/4885HPGD 171/4885 |
| US-20250206745-A1 | PYRROLOPYRIDAZINE DERIVATIVES AND RELATED USES | IL1B, NLRP3, NLRP1 | HIF1A 1424/4885ALDH1A1 226/4885HPGD 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.